Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiencies

Trial Profile

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiencies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs TBX 1400 (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Aug 2016 Status changed from planning to not yet recruiting.
    • 17 Jun 2016 New trial record
    • 13 Jun 2016 According to a Taiga Biotechnologies media release, the U.S.FDA granted Orphan Drug Designation to TBX-1400 for the treatment of Severe Combined ImmunoDeficiency in children.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top